4AJ0.F ALK-ABELLO AS DK -50

Healthcare Biotechnology Frankfurt Exchange
36.23 EUR
Close of Nov 11, 2026
25.68 36.28
Market cap
EUR 7.29B
P/E
39.7x
P/B
7.86x
ROE
22.4%
Dividend yield
0.66%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 4AJ0.F undervalued?

Graham number

The Graham number of ALK-ABELLO AS DK -50 cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

ALK-ABELLO AS DK -50 fundamental analysis

No fundamental analysis for ALK-ABELLO AS DK -50 yet.

ALK-ABELLO AS DK -50 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About ALK-ABELLO AS DK -50

ALK-Abelló A/S, an allergy solutions company, develops treatments for respiratory allergy, anaphylaxis, and food allergy and new disease areas in the European Union, the United Kingdom, Norway, Switzerland, the United States, Canada, Japan, China, and internationally. The company offers allergy immunotherapy products in the form of vaccines, injections, sublingual drops, and tablets for the treatment of various allergies, including grass and tree pollen, house dust mites, ra…

Full company profile